Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The investigators' central hypothesis is that early combination therapy with two PAH-specific
oral therapies that have been shown to be well tolerated in the pediatric population,
sildenafil and bosentan, will result in better World Health Organization (WHO) functional
class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.